Department of Clinical Genomics, Mayo Clinic, Rochester, MN 55905, USA.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
Cell Rep. 2024 Mar 26;43(3):113883. doi: 10.1016/j.celrep.2024.113883. Epub 2024 Mar 1.
Phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG) is a rare inborn error of metabolism caused by deficiency of the PMM2 enzyme, which leads to impaired protein glycosylation. While the disorder presents with primarily neurological symptoms, there is limited knowledge about the specific brain-related changes caused by PMM2 deficiency. Here, we demonstrate aberrant neural activity in 2D neuronal networks from PMM2-CDG individuals. Utilizing multi-omics datasets from 3D human cortical organoids (hCOs) derived from PMM2-CDG individuals, we identify widespread decreases in protein glycosylation, highlighting impaired glycosylation as a key pathological feature of PMM2-CDG, as well as impaired mitochondrial structure and abnormal glucose metabolism in PMM2-deficient hCOs, indicating disturbances in energy metabolism. Correlation between PMM2 enzymatic activity in hCOs and symptom severity suggests that the level of PMM2 enzyme function directly influences neurological manifestations. These findings enhance our understanding of specific brain-related perturbations associated with PMM2-CDG, offering insights into the underlying mechanisms and potential directions for therapeutic interventions.
磷酸甘露糖变位酶 2-先天性糖基化障碍(PMM2-CDG)是一种由 PMM2 酶缺乏引起的罕见先天性代谢缺陷,导致蛋白质糖基化受损。虽然该疾病主要表现为神经系统症状,但对于 PMM2 缺乏引起的特定脑部相关变化知之甚少。在这里,我们展示了来自 PMM2-CDG 个体的 2D 神经元网络中异常的神经活动。利用来自 PMM2-CDG 个体的 3D 人皮质类器官(hCO)的多组学数据集,我们发现蛋白质糖基化广泛减少,突出了糖基化缺陷是 PMM2-CDG 的关键病理特征,以及 PMM2 缺陷的 hCO 中线粒体结构和异常葡萄糖代谢受损,表明能量代谢紊乱。hCO 中 PMM2 酶活性与症状严重程度之间的相关性表明,PMM2 酶功能的水平直接影响神经系统表现。这些发现增强了我们对与 PMM2-CDG 相关的特定脑部相关扰动的理解,为潜在的治疗干预提供了潜在机制和方向的见解。